Form 8-K - Current report:
SEC Accession No. 0001104659-23-046719
Filing Date
2023-04-18
Accepted
2023-04-18 16:15:26
Documents
13
Period of Report
2023-04-17
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2312947d1_8k.htm   iXBRL 8-K 33551
2 EXHIBIT 16.1 tm2312947d1_ex16-1.htm EX-16.1 2882
  Complete submission text file 0001104659-23-046719.txt   212073

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apre-20230417.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20230417_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20230417_pre.xml EX-101.PRE 22589
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2312947d1_8k_htm.xml XML 3606
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 23827012
SIC: 2834 Pharmaceutical Preparations